Advanced and controlled drug delivery systems in clinical disease management

被引:36
作者
Brouwers, JRBJ
机构
[1] GUIDE, Div. Pharmacokin./Clinical Pharmacy, Dept. Soc. Pharmacy/Pharmacoepidem., 9713 AW Groningen
来源
PHARMACY WORLD & SCIENCE | 1996年 / 18卷 / 05期
关键词
advanced drug delivery; controlled drug delivery; clinical practice; review;
D O I
10.1007/BF00820726
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Advanced and controlled drug delivery systems are important for clinical disease management. In this review the most important new systems which have reached clinical application are highlighted. Microbiologically controlled drug delivery is important for gastrointestinal diseases like ulcerative colitis and distally controlled release systems have improved patient compliance and decreased side effects. In the treatment of intractable pain the spinal and transdermal route is well documented. In neurology the flattened peak-through levels of antiepileptic drugs and anti Parkinson's drugs represents a more predictable kinetic profile. Tracheal delivery of corticosteroids and sympaticommimetics in asthma and Chronic Obstructive Pulmonary Disease is fully accepted in clinical practice: delivery by this route results in better efficacy and a better safety profile. In gynaecology the delivery of pulsatile hormones (LHRH) is used for pregnancy induction, while transdermal oestrogens are promising in the prevention of osteoporosis. In surgical practice the use of antibiotic impregnated bone cement and antibiotic impregnated biodegradable collagens is well established. To prevent infections intravascular catheters coated with heparin or antibiotics are used. In ophthalmology the Ocusert(R) systems provide a controlled release of different drugs in the eye. Most spectacular is the clinical introduction of the first liposomal drugs: amfotericine B and daunorubicine. Liposomal formulations of these drugs have enhanced activity and decreased toxicity compared to conventional formulations.
引用
收藏
页码:153 / 162
页数:10
相关论文
共 93 条
[1]   CONTINUOUS INTRATHECAL BACLOFEN INFUSION FOR SPASTICITY OF CEREBRAL ORIGIN [J].
ALBRIGHT, AL ;
BARRON, WB ;
FASICK, MP ;
POLINKO, P ;
JANOSKY, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (20) :2475-2477
[2]   DOES SURFACE HEPARINIZATION REDUCE BACTERIAL-COLONIZATION OF CENTRAL VENOUS CATHETERS [J].
APPELGREN, P ;
RANSJO, U ;
BINDSLEV, L ;
LARM, O .
LANCET, 1995, 345 (8942) :130-130
[3]  
BADLER M, 1994, BIOPHARM DRUG DISPOS, V15, P45
[4]   PROSTHETIC GRAFT INFECTION [J].
BANDYK, DF ;
ESSES, GE .
SURGICAL CLINICS OF NORTH AMERICA, 1994, 74 (03) :571-590
[5]  
BEGLINGER C, 1993, BR J CLIN PHARM, V33, P39
[6]  
BERGAMINI TM, 1994, VASC FORUM, V2, P92
[7]   LIPOSOMES AS DELIVERY SYSTEMS IN THE PREVENTION AND TREATMENT OF INFECTIOUS-DISEASES [J].
BERGERS, JJ ;
TENHAGEN, TLM ;
VANETTEN, EWM ;
BAKKERWOUDENBERG, IAJM .
PHARMACY WORLD & SCIENCE, 1995, 17 (01) :1-11
[8]  
BJARNASON I, 1993, INFLAMMOPHARMACOL, V3, P277
[9]   GENE-THERAPY - A NOVEL FORM OF DRUG-DELIVERY [J].
BLAU, HM ;
SPRINGER, ML .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (18) :1204-1207
[10]  
BRAAT DDM, 1992, THESIS FREE U AMSTER